Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)[1], 18 November 2015
Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notifications:
-
On 13 November 2015, Fagron received a notification that the shareholding of FMR LLC has fallen below the disclosure threshold of 3% through the disposal of voting securities.
-
On 16 November 2015, Fagron received a notification that the shareholding of Consonance Capital Management LP has fallen below the disclosure threshold of 3% through the disposal of voting securities.
-
On 17 November 2015, Fagron received a notification that the shareholding of BNP Paribas Investment Partners SA has fallen below the disclosure threshold of 3% through the disposal of voting securities.
Based on the denominator of 32,111,827 (total number of voting rights) and the latest received notifications, the major shareholders of Fagron are:
Number of shares % of effective voting rights Carmignac Gestion 2,463,267 7.67% Alychlo NV / Marc Coucke 1,709,601 5.32% TIAA-CREF Asset Management LLC 1,635,681 5.09%The original notification forms are available on the website investors.fagron.com.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
For further information
Constantijn van Rietschoten
Chief Marketing Officer / Investor Relations a.i.
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Fagron profile
Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
Please open the link below for the press release: